



## Ortho Regenerative Technologies Announces Final Closing of its Non-Brokered Private Placement

***NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES***

**Kirkland, QC, December 11, 2017** – Ortho Regenerative Technologies Inc. (CSE: **ORTH.CN**) (“**Ortho RTi**” or the “**Corporation**”) is pleased to announce that, further to its news release of October 31, 2017, it has issued a total of 320,000 additional units (the “**Units**”) pursuant to its previously announced non-brokered private placement (the “**Private Placement**”). The Units were sold at price per Unit of \$0.50, for total gross proceeds to the Corporation of \$160,000. Including the initial issuance of 1,810,000 Units, the Private Placement as a whole resulted in the issuance by the Company of a total of 2,170,000 Units for total gross proceeds of \$1,065,000.

Each Unit issued consists of one Class “A” common share of the Corporation (the “**Share**”) and one-half (½) of one non-transferable Share purchase warrant (each whole Share purchase warrant, a “**Warrant**”) of the Corporation. Each whole Warrant entitles the holder thereof to acquire one Share of the Corporation at an exercise price of \$0.70 per Share at any time on or before the close of business on a date that is eighteen (18) months from the Closing Date (as hereinafter defined). If, during the eighteen (18) months after the Closing Date, the Corporation's weighted average Share price for 30 consecutive trading days equals or exceeds \$1.00, the Corporation may give notice to the Warrant holders that they must exercise their remaining Warrants within a period of 30-days from the date of receipt of the notice.

In connection with this final closing, the Corporation paid a cash commission of \$5,500 and issued 11,000 non-transferable share purchase warrants (the “**Finder Warrants**”). The Finder Warrants are subject to the same terms and conditions as the Warrants.

“The total net proceeds from this private placement, combined with the approximate \$2.7 million raised in previous recent financings, provides OrthoRTi with the necessary financial resources to continue advancing our development programs,” said the Corporation’s Executive Chairman and CEO, Dr. Brent Norton. “We look forward to updating all of our stakeholders on our progress as we complete our work of creating a best-in-class product and moving it into the clinic.”

The net proceeds from the Private Placement will be used to fund research and development costs and for general corporate purposes of the Corporation.

*This press release does not constitute an offer to sell or a solicitation of an offer to buy securities in the United States. The securities referenced herein have not been and will not be registered under the United States Securities Act of 1933, as amended (the “U.S. Securities Act”), or any state securities laws and may not be offered or sold in the United States except in compliance with one or more exemptions from the registration requirements of the U.S. Securities Act and applicable securities laws.*



## **About Ortho Regenerative Technologies Inc.**

Ortho RTi is an emerging Orthopaedic and Sports Medicine technology company dedicated to the development of novel therapeutic tissue repair technology to dramatically improve the success rate of sports medicine surgeries for soft tissue injuries. Our proprietary biopolymer has been specifically designed to increase the healing rates of injuries to tendons, meniscus and cartilage. The polymer can be directly placed into the site of injury by a surgeon during a routine operative procedure without significantly extending the time of the surgery and without further intervention. Visit us on the internet at [www.orthorti.com](http://www.orthorti.com).

## ***Forward-Looking Statements***

*This news release may contain certain forward-looking statements regarding the Corporation's expectations for future events. Such expectations are based on certain assumptions that are founded on currently available information. If these assumptions prove incorrect, actual results may differ materially from those contemplated by the forward-looking statements contained in this press release. Factors that could cause actual results to differ include, amongst others, uncertainty as to the final result and other risks. The Corporation disclaims any intention or obligation to publicly update or revise any forward- looking statements, whether as a result of new information, future events or otherwise, other than as required by security laws.*

For further Information, please contact:

Stephen Kilmer  
Investor & Media Relations  
647.872.4849  
kilmer@orthorti.com